These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 8744535)

  • 21. Relative risk reduction versus number needed to treat as measures of lipid-lowering trial results.
    Moriarty PM
    Am J Cardiol; 1998 Aug; 82(4):505-7. PubMed ID: 9723640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid disorders in NIDDM: implications for treatment.
    Taskinen MR; Smith U
    J Intern Med; 1998 Nov; 244(5):361-70. PubMed ID: 9845851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Statins (HMG-CoA reductase inhibitors)].
    Gotoda T
    Nihon Rinsho; 2006 Nov; 64(11):2113-8. PubMed ID: 17087305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should hyperlipidaemia in dialysis patients be treated?
    Wheeler DC
    Nephrol Dial Transplant; 1997 Jan; 12(1):19-21. PubMed ID: 9027766
    [No Abstract]   [Full Text] [Related]  

  • 25. Lipids and progressive renal disease: the cardio-renal link.
    Keane WF
    Am J Kidney Dis; 1999 Aug; 34(2):xliii-xlvi. PubMed ID: 10465726
    [No Abstract]   [Full Text] [Related]  

  • 26. Lipid-lowering therapy in patients with renal disease.
    Massy ZA; Ma JZ; Louis TA; Kasiske BL
    Kidney Int; 1995 Jul; 48(1):188-98. PubMed ID: 7564077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms underlying reduction of clinical events in lipid lowering trials.
    Mancini GB
    Can J Cardiol; 1995 May; 11 Suppl C():15C-17C. PubMed ID: 7750043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
    Florkowski CM
    Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug treatment of hyperlipidemia in women.
    Walsh JM; Pignone M
    JAMA; 2004 May; 291(18):2243-52. PubMed ID: 15138247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Practical drug therapy for common hyperlipidaemias.
    Tikkanen MJ
    Baillieres Clin Endocrinol Metab; 1990 Dec; 4(4):719-42. PubMed ID: 2082904
    [No Abstract]   [Full Text] [Related]  

  • 31. [Dyslipidemia and thrombosis: what role for therapeutics?].
    Ambrosi P; Luccioni R
    Rev Med Interne; 1997; 18 Suppl 2():94s-95s. PubMed ID: 9239379
    [No Abstract]   [Full Text] [Related]  

  • 32. Currently available lipid-lowering agents.
    Levy RI
    Hosp Pract (Off Ed); 1988 Jun; 23 Suppl 1():14-21. PubMed ID: 3134381
    [No Abstract]   [Full Text] [Related]  

  • 33. Lipid-lowering drugs in the management of hyperlipidaemia.
    Bhatnagar D
    Pharmacol Ther; 1998 Sep; 79(3):205-30. PubMed ID: 9776377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease.
    Kostis JB
    Cardiovasc Drugs Ther; 2007 Aug; 21(4):297-309. PubMed ID: 17605096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nutritional and medical therapy for dyslipidemia in patients with cardiovascular disease.
    Logan P; Clarke S
    AACN Clin Issues; 2001 Feb; 12(1):40-52. PubMed ID: 11288327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New drugs for reducing cardiovascular risk in women.
    Thacker HL; Saadi H
    Cleve Clin J Med; 1997 Oct; 64(9):493-502. PubMed ID: 9339048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fenofibric acid for hyperlipidemia.
    Saurav A; Kaushik M; Mohiuddin SM
    Expert Opin Pharmacother; 2012 Apr; 13(5):717-22. PubMed ID: 22404421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review.
    Yao YS; Li TD; Zeng ZH
    Lipids Health Dis; 2020 Feb; 19(1):23. PubMed ID: 32035485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vestibular vertigo associated with hyperlipidemia: response to antilipidemic therapy.
    Saadah HA
    Arch Intern Med; 1993 Aug; 153(15):1846, 1849. PubMed ID: 8333820
    [No Abstract]   [Full Text] [Related]  

  • 40. Lipid management in the proteinuric patient: do not overlook the importance of proteinuria reduction.
    Vogt L; Laverman GD; Dullaart RP; Navis G
    Nephrol Dial Transplant; 2004 Jan; 19(1):5-8. PubMed ID: 14671028
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.